mk-0557 has been researched along with Obesity* in 4 studies
3 trial(s) available for mk-0557 and Obesity
Article | Year |
---|---|
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.
To evaluate whether MK-0557, a highly selective, orally administered neuropeptide Y Y5 receptor antagonist, could limit weight regain after very-low-calorie diet (VLCD)-induced weight loss.. We enrolled 502 patients 18 to 65 years of age with a BMI of 30 to 43 kg/m2. Patients were placed on a VLCD (800 kcal/d liquid diet) for 6 weeks. Patients who lost>or=6% of initial body weight (n=359) were randomized to 52 weeks of 1 mg/d MK-0557 or placebo and maintained on a hypocaloric diet (300 kcal below weight maintenance requirements).. In randomized patients, the VLCD was associated with an average weight loss of 9.1 kg. After 12 weeks of double-blind treatment, weight began to gradually increase for both placebo- and MK-0557-treated patients. The mean weight change (95% confidence interval) from baseline at the end of the VLCD to Week 52 was +3.1 (2.1, 4.0) and +1.5 (0.5, 2.4) kg for patients treated with placebo and MK-0557, respectively. The difference of 1.6 kg between the two groups was significant (p=0.014). Secondary endpoints, such as blood pressure, lipid profile, insulin, and leptin, as well as waist circumference and quality-of-life measurements, did not show significant differences between MK-0557 and placebo treatments.. Although the difference in weight regain between placebo- and MK-0557-treated patients was statistically significant, the magnitude of the effect was small and not clinically meaningful. Antagonism of the neuropeptide Y Y5 receptor is not an efficacious treatment strategy for reducing weight regain after VLCD. Topics: Adolescent; Adult; Aged; Body Mass Index; Caloric Restriction; Cyclohexanes; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurotransmitter Agents; Obesity; Placebos; Pyrazoles; Receptors, Neuropeptide Y; Spiro Compounds; Weight Loss | 2007 |
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Central counter-regulatory mechanisms, including those related to the orexigenic hormone neuropeptide Y (NPY), may limit the weight loss observed with conventional pharmacological monotherapy. This study evaluated whether blockade of the NPY Y5 receptor (NPY5R) with the selective antagonist MK-0557 potentiates sibutramine and orlistat weight loss effects.. Obese patients (497, BMI 30 to 43 kg/m2) were randomized to 1 of 5 treatment arms [placebo, n = 101; sibutramine 10 mg/d, n = 100; MK-0557 1 mg/d plus sibutramine 10 mg/d, n = 98; orlistat 120 mg TID, n = 99; MK-0557 1 mg/d plus orlistat 120 mg TID, n = 99] in conjunction with a hypocaloric diet for 24 weeks. The all-patients-treated population, imputing missing data using last observation carried forward, was used to assess weight loss from baseline.. The study was completed by 71% of patients in placebo, 76% in sibutramine alone, 79% in MK-0557 + sibutramine, 69% in orlistat alone, and 76% in MK-0557 + orlistat groups. Least squares (LS) mean difference [95% confidence interval (CI)] in weight change from baseline between MK-0557 + sibutramine and sibutramine alone was -0.1 (-1.6, 1.4) kg (p = 0.892) and between MK-0557 + orlistat and orlistat alone was -0.9 (-2.4, 0.6) kg (p = 0.250). Sibutramine alone induced a LS mean weight loss of -5.9 (-6.9, -4.9) kg vs. -4.6 (-5.7, -3.6) kg for orlistat (p = 0.097). There were no serious drug-related adverse events and MK-0557 was well tolerated.. Blockade of the NPY5R with the potent antagonist MK-0557 did not significantly increase the weight loss efficacy of either orlistat or sibutramine monotherapy. Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cyclobutanes; Cyclohexanes; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Pyrazoles; Receptors, Neuropeptide Y; Spiro Compounds; Weight Loss | 2007 |
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and NPY Y5 receptors (NPYxR) is considered a potentially important anti-obesity drug target. We tested the hypothesis that blockade of the NPY5R will lead to weight loss in humans using MK-0557, a potent, highly selective, orally active NPY5R antagonist. The initial series of experiments reported herein, including a multiple-dose positron-emission tomography study and a 12 week proof-of concept/dose-ranging study, suggested an optimal MK-0557 dose of 1 mg/day. The hypothesis was then tested in a 52 week, multicenter, randomized, double-blind, placebo-controlled trial involving 1661 overweight and obese patients. Although statistically significant at 52 weeks, the magnitude of induced weight loss was not clinically meaningful. These observations provide the first clinical insight into the human NPY-energy homeostatic pathway and suggest that solely targeting the NPY5R in future drug development programs is unlikely to produce therapeutic efficacy. Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Obesity Agents; Body Weight; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Middle Aged; Molecular Structure; Obesity; Placebos; Positron-Emission Tomography; Pyrazoles; Receptors, Neuropeptide Y; Sensitivity and Specificity; Spiro Compounds; Structure-Activity Relationship; Treatment Outcome | 2006 |
1 other study(ies) available for mk-0557 and Obesity
Article | Year |
---|---|
Obesity and the central nervous system.
Topics: Animals; Anti-Obesity Agents; Central Nervous System; Cyclohexanes; Energy Metabolism; Feeding Behavior; Humans; Leptin; Obesity; Pyrazoles; Receptors, Leptin; Receptors, Neuropeptide Y; Signal Transduction; Spiro Compounds; Weight Gain | 2007 |